Latanoprost controlled release - Peregrine Ophthalmic

Drug Profile

Latanoprost controlled release - Peregrine Ophthalmic

Alternative Names: Latanoprost extended release -Preregrine Ophthalmic; Latanoprost liposomal - Peregrine Ophthalmic; POLAT 001

Latest Information Update: 28 Jun 2016

Price : $50

At a glance

  • Originator Peregrine Ophthalmic
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Jun 2016 Peregrine Ophthalmic completes an observational, extension clinical trial for Glaucoma and Ocular hypertension in USA (Ophthalmic) (NCT02599688)
  • 01 Apr 2016 Peregrine Ophthalmic completes a phase II trial in Glaucoma and Ocular hypertension in USA (Ophthalmic) (NCT02466399)
  • 01 Nov 2015 Peregrine Ophthalmic initiates an observational, extension clinical trial for Glaucoma in USA (Ophthalmic) (NCT02599688)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top